Investigation of the vaccine potential of an designed FepA peptide vaccine against in mice model.

Background: Shigellosis is one of the significant causes of diarrhea in Bangladesh. It is a global health problem; approximately 1.3 million people die yearly from Shigellosis. The current treatment method, using different antibiotics against Shigellosis is ineffective. Moreover, it becomes a worrying situation due to the emergence of antibiotic-resistant pathogenic microbes responsible for these diarrheal diseases.

Methodology: Previous immunoinformatics study predicted a potential peptide from the Ferric enterobactin protein (FepA) of spp. In this study, we have chemically synthesized the FepA peptide. As a highly immunogenic, FepA peptide conjugated with KLH has been tested in mice model with complete and incomplete adjuvants as a vaccine candidate.

Results: Immunological analysis showed that all vaccinated mice were immunologically boosted, which was statistically significant (value 0.0325) compared to control mice. Immunological analysis for bacterial neutralization test result was also statistically significant (-value 0.0468), where each ELISA plate was coated with 1 × 10 cells. The Challenge test with 1 × 10 cells to each vaccinated and controlled mice showed that 37.5 % of control (non-vaccinated) mice died within seven days after the challenge was given while 100 % of vaccinated mice remained strong and stout. The analyses of the post-challenge weight loss of the mice were also significant (-value 0.0367) as the weight loss percentage in control mice was much higher than in the vaccinated mice. The pathological and phenotypic appearances of vaccinated mice were also clearly differentiable compared with control mice. Thus all these immunological analysis and pathological appearances directly supported our FepA peptide as a potential immune booster.

Conclusion: This study provides evidence that the FepA peptide is a highly immunogenic vaccine candidate against . Therefore, these findings inspire future trials for the evaluation of the suitability of this vaccine candidate against Shigellosis.